XML 63 R52.htm IDEA: XBRL DOCUMENT v3.23.3
Collaboration, License, and Other Agreements - Other Collaboration and License Agreements (Details)
$ in Thousands, ¥ in Millions
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Apr. 30, 2023
USD ($)
Mar. 31, 2022
USD ($)
Mar. 31, 2022
JPY (¥)
Nov. 30, 2021
USD ($)
Sep. 30, 2023
USD ($)
Jun. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Dec. 31, 2021
USD ($)
Jun. 28, 2023
USD ($)
Dec. 31, 2022
USD ($)
Mar. 31, 2022
JPY (¥)
Collaboration, License, Promotion and Other Commercial Agreements                          
Revenue         $ 113,739   $ 108,637 $ 325,182 $ 303,397        
Deferred revenue, current         2,600     2,600          
Research and development expense         32,985   11,545 80,409 33,819        
Accrued research and development costs         10,735     10,735       $ 5,258  
COUR Pharmaceuticals Development Company, Inc.                          
Collaboration, License, Promotion and Other Commercial Agreements                          
Collaborative arrangement, upfront payment $ 6,000     $ 6,000                  
Collaborative arrangement, non-contingent payments and milestone payments, payable       $ 13,500                  
Collaborative arrangement, option to acquire license, exercise price, payable         35,000     35,000          
Collaborative arrangement, milestones. potential commercial milestone payments, term of agreement, payable         440,000     440,000          
Research and development expense           $ 6,000       $ 19,500      
Accrued research and development costs         0     0       $ 3,800  
Collaborative arrangement, right to apply credit against future amounts due $ 6,600                        
Asahi Kasei Pharma Corporation                          
Collaboration, License, Promotion and Other Commercial Agreements                          
Deferred revenue, current         2,600     2,600          
Deferred revenue, noncurrent         600     600          
Deferred revenue                     $ 4,300    
Collaborative arrangement, upfront payment received   $ 24,600 ¥ 3,000                    
Collaborative arrangement, development related payment, eligible to receive   13,100                     ¥ 1,600
Collaborative arrangement, development milestones, eligible to receive   8,200                     1,000
Collaborative arrangement, commercial and sales-based milestone payments, eligible to receive   $ 155,800                     ¥ 19,000
Asahi Kasei Pharma Corporation | Collaborative arrangement, development and commercialization agreements                          
Collaboration, License, Promotion and Other Commercial Agreements                          
Revenue         $ 934     $ 997          
Alnylam | Royalty                          
Collaboration, License, Promotion and Other Commercial Agreements                          
Revenue             $ 814   $ 2,222